Manufacturers Life Insurance Company, The Eq Rx, Inc. Transaction History

Manufacturers Life Insurance Company, The

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$1.66 - $2.31 $11,306 - $15,733	-6,811 Reduced 4.94%	130,989 $290,000
Q2 2023 Aug 11, 2023	SELL	$1.61 - $1.96 $99,626 - $121,284	-61,880 Reduced 30.99%	137,800 $256,000
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $198,993 - $312,862	-110,552 Reduced 55.36%	89,128 $172,000
Q4 2022 Aug 11, 2023	BUY	$2.05 - $5.5 $55,366 - $148,544	27,008 Added 15.64%	199,680 $491,000
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $55,366 - $148,544	27,008 Added 15.64%	199,680 $491,000
Q3 2022 Aug 11, 2023	SELL	$0.94 - $5.99 $1,470 - $9,368	-1,564 Reduced 0.9%	172,672 $854,000
Q3 2022 Nov 03, 2022	SELL	$0.94 - $5.99 $1,470 - $9,368	-1,564 Reduced 0.9%	172,672 $855,000
Q2 2022 Aug 11, 2023	BUY	$3.2 - $5.69 $167,331 - $297,535	52,291 Added 42.88%	174,236 $817,000
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.69 $167,331 - $297,535	52,291 Added 42.88%	174,236 $805,000
Q1 2022 Aug 11, 2023	BUY	$2.8 - $7.39 $91,887 - $242,517	32,817 Added 36.82%	121,945 $503,000
Q1 2022 May 20, 2022	BUY	$2.8 - $7.39 $341,446 - $901,173	121,945 New	121,945 $511,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.